Merxin Ltd has been honoured with a King’s Award for Enterprise for Innovation.
Merxin Ltd is one of only 185 organisations nationally to be recognised with a prestigious King’s Award for Enterprise in 2026. Announced today (Wednesday 6 May at 1pm in the Royal Gazette). The Award acknowledges the company’s outstanding achievement in Innovation.
Employing 21 people, Merxin Ltd is a biotech company founded in 2015 and based in King’s Lynn, Norfolk, U.K.. The company designs and supplies devices for inhaled therapies.
Their innovation, MRX004, is a soft mist inhaler enabling precision drug delivery whilst minimising environmental impact. The global soft mist inhaler market has long been dominated by proprietary devices, limiting pharmaceutical companies’ options, raising treatment costs, and restricting patient access. Current inhalers have either low performance or high environmental impact. MRX004 addresses these shortcomings through a variable-dose firing mechanism, optimised aerosolisation options for improved respiratory tract delivery, and a design engineered for low global warming potential. Multiple patents protect the innovation.
Commercial contracts have been secured with blue chips companies in Europe and in the United States, with further growth anticipated from 2027.
“This Award is a proud moment for everyone at Merxin Ltd and a testament to ten years of outstanding innovation by an exceptional team. Graham and I are deeply honoured by the recognition from His Majesty The King and the Prime Minister. We are excited about what this milestone means for our future.” said Philippe Rogueda, Chief Business Officer and co-founder.
To Learn More about Merxin Ltd visit: https://www.merxin.com
Contact: Philippe Rogueda, CBO; (44) 01553 403070, philippe@merxin.com
